Reuters - 22 January 2018, 17:08 (+ 2288 days 7 hours and 56 minutes) Health
LONDON (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets.